Julian Simon

Summary

Affiliation: Fred Hutchinson Cancer Research Center
Country: USA

Publications

  1. ncbi request reprint Yeast as a model system for anticancer drug discovery
    J A Simon
    Program in Molecular Pharmacology, Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue North, Seattle, WA 98109, USA
    Expert Opin Ther Targets 5:177-95. 2001
  2. pmc Non-specific chemical inhibition of the Fanconi anemia pathway sensitizes cancer cells to cisplatin
    Céline Jacquemont
    Howard Hughes Medical Institute, Chevy Chase, MD, USA
    Mol Cancer 11:26. 2012
  3. ncbi request reprint [Chemistry and biology of NAD-dependent deacetylases]
    Julian A Simon
    Fred Hutchinson Cancer Research Center, USA
    Tanpakushitsu Kakusan Koso 50:1049-55. 2005
  4. ncbi request reprint Using isoform-specific inhibitors to target lipid kinases
    Julian A Simon
    Clinical Research and Human Biology Divisions, Fred Hutchinson Cancer Research Center, D2 100, 1100 Fairview Avenue North, Seattle, WA 98109, USA
    Cell 125:647-9. 2006
  5. ncbi request reprint Yeast as a model system for anticancer drug discovery
    Julian A Simon
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA
    Nat Rev Cancer 4:481-92. 2004
  6. ncbi request reprint Identification of selective inhibitors of NAD+-dependent deacetylases using phenotypic screens in yeast
    Maki Hirao
    Divisions of Clinical Research and Human Biology, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109, USA
    J Biol Chem 278:52773-82. 2003
  7. ncbi request reprint Neuroscience. NAD to the rescue
    Antonio Bedalov
    Clinical Research Division and J A Simon is in the Clinical Research and Human Biology Divisions, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    Science 305:954-5. 2004
  8. ncbi request reprint Inhibitors of Sir2: evaluation of splitomicin analogues
    Jeff Posakony
    Clinical Research and Human Biology Divisions, Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue North, Seattle, Washington 98109, USA
    J Med Chem 47:2635-44. 2004
  9. pmc NAD+-dependent deacetylase Hst1p controls biosynthesis and cellular NAD+ levels in Saccharomyces cerevisiae
    Antonio Bedalov
    Clinical Research and Human Biology Divisions, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109, USA
    Mol Cell Biol 23:7044-54. 2003
  10. ncbi request reprint Antitumor activity of a small-molecule inhibitor of human silent information regulator 2 enzymes
    Birgit Heltweg
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109, USA
    Cancer Res 66:4368-77. 2006

Research Grants

  1. NOVEL DOUBLE STRAND BREAK PRODUCING COMPOUNDS
    Julian Simon; Fiscal Year: 2001
  2. STRATEGIES FOR CONTEXT SPECIFIC ANTICANCER THERAPIES
    Julian Simon; Fiscal Year: 2002
  3. New mitosis specific anticancer agents
    Julian Simon; Fiscal Year: 2005

Collaborators

  • Antonio Bedalov
  • David R H Evans
  • J R Lamb
  • RONALD ANTHONY DEPINHO
  • Tonibelle Gatbonton
  • Jeff Posakony
  • Céline Jacquemont
  • Allison B Coffin
  • Maki Hirao
  • David W Raible
  • Edwin W Rubel
  • Henry C Ou
  • John R Chevillet
  • Safia Thaminy
  • Birgit Heltweg
  • Melisa Nelson
  • Sondra Goehle
  • P Clint Spiegel
  • Heather M Dunstan
  • ALAN D D'ANDREA
  • Toshiyasu Taniguchi
  • Henry Ou
  • Kelly N Owens
  • Felipe Santos
  • Carlene S Brandon
  • Lisa L Cunningham
  • Shimon P Francis
  • Valeri I Vasioukhin
  • Gemma J Park
  • Jessica Kim
  • Eric Foss
  • Benjamin Newcomb
  • Maria Imbesi
  • Leonid Kruglyak
  • Ramya Kollipara
  • Aaron D Schuler
  • Yansong Gu
  • Douglas M Ruderfer
  • Hongzhe Li
  • Joshua M Akey
  • Barry L Stoddard
  • Sam Stevens
  • Shari M Kaiser
  • Jeffrey Posakony
  • Manfred Jung
  • Henning Hruby
  • Michelle Cronk
  • Philippe Szankasi
  • Catherine Ludlow

Detail Information

Publications19

  1. ncbi request reprint Yeast as a model system for anticancer drug discovery
    J A Simon
    Program in Molecular Pharmacology, Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue North, Seattle, WA 98109, USA
    Expert Opin Ther Targets 5:177-95. 2001
    ..The methodologies covered include pharmacological and genetic screens, as well as genome-wide approaches to drug target identification...
  2. pmc Non-specific chemical inhibition of the Fanconi anemia pathway sensitizes cancer cells to cisplatin
    Céline Jacquemont
    Howard Hughes Medical Institute, Chevy Chase, MD, USA
    Mol Cancer 11:26. 2012
    ....
  3. ncbi request reprint [Chemistry and biology of NAD-dependent deacetylases]
    Julian A Simon
    Fred Hutchinson Cancer Research Center, USA
    Tanpakushitsu Kakusan Koso 50:1049-55. 2005
  4. ncbi request reprint Using isoform-specific inhibitors to target lipid kinases
    Julian A Simon
    Clinical Research and Human Biology Divisions, Fred Hutchinson Cancer Research Center, D2 100, 1100 Fairview Avenue North, Seattle, WA 98109, USA
    Cell 125:647-9. 2006
    ..In a related Cancer Cell paper, Fan et al. (2006) show that blocking activation of both p110alpha and the kinase mTOR with a small molecule inhibitor limits the growth of gliomas...
  5. ncbi request reprint Yeast as a model system for anticancer drug discovery
    Julian A Simon
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA
    Nat Rev Cancer 4:481-92. 2004
  6. ncbi request reprint Identification of selective inhibitors of NAD+-dependent deacetylases using phenotypic screens in yeast
    Maki Hirao
    Divisions of Clinical Research and Human Biology, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109, USA
    J Biol Chem 278:52773-82. 2003
    ..Selectivity was affirmed using whole-genome DNA microarray analysis. This study underscores the power of phenotypic screens in the development and characterization of selective inhibitors of enzyme functions...
  7. ncbi request reprint Neuroscience. NAD to the rescue
    Antonio Bedalov
    Clinical Research Division and J A Simon is in the Clinical Research and Human Biology Divisions, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    Science 305:954-5. 2004
  8. ncbi request reprint Inhibitors of Sir2: evaluation of splitomicin analogues
    Jeff Posakony
    Clinical Research and Human Biology Divisions, Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue North, Seattle, Washington 98109, USA
    J Med Chem 47:2635-44. 2004
    ..Lactone hydrolysis rates were used as a measure of reactivity; hydrolysis rates correlate with inhibitory activity. The most potent Sir2 inhibitors were structurally similar to and had hydrolysis rates similar to 1...
  9. pmc NAD+-dependent deacetylase Hst1p controls biosynthesis and cellular NAD+ levels in Saccharomyces cerevisiae
    Antonio Bedalov
    Clinical Research and Human Biology Divisions, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109, USA
    Mol Cell Biol 23:7044-54. 2003
    ..These findings suggest that Hst1p serves as a cellular NAD(+) sensor that monitors and regulates cellular NAD(+) levels...
  10. ncbi request reprint Antitumor activity of a small-molecule inhibitor of human silent information regulator 2 enzymes
    Birgit Heltweg
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109, USA
    Cancer Res 66:4368-77. 2006
    ..Cambinol was well tolerated in mice and inhibited growth of Burkitt lymphoma xenografts. Inhibitors of NAD-dependent deacetylases may constitute novel anticancer agents...
  11. ncbi request reprint Novel approaches to screen for anticancer drugs using Saccharomyces cerevisiae
    Julian A Simon
    Program in Molecular Pharmacology, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
    Methods Mol Biol 223:555-76. 2003
  12. pmc Telomere length as a quantitative trait: genome-wide survey and genetic mapping of telomere length-control genes in yeast
    Tonibelle Gatbonton
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA
    PLoS Genet 2:e35. 2006
    ..Furthermore, our results laid the foundation for studying genetic determinants of telomere length-variation and their roles in human disease...
  13. ncbi request reprint Hst3 is regulated by Mec1-dependent proteolysis and controls the S phase checkpoint and sister chromatid cohesion by deacetylating histone H3 at lysine 56
    Safia Thaminy
    Clinical Research Division and Human Biology Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    J Biol Chem 282:37805-14. 2007
    ..Both S phase checkpoint and SCC defects are phenocopied by H3K56 point mutants. Our findings demonstrate that Hst3-regulated H3K56 acetylation safeguards genome stability by controlling the S phase DNA damage response and promoting SCC...
  14. ncbi request reprint Sir2 flexes its muscle
    Antonio Bedalov
    Clinical Research and Human Biology Divisions, Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue North, D2 100, Seattle, WA 98107, USA
    Dev Cell 5:188-9. 2003
    ....
  15. ncbi request reprint Cell-based assays for identification of novel double-strand break-inducing agents
    Heather M Dunstan
    Program in Molecular Pharmacology, Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
    J Natl Cancer Inst 94:88-94. 2002
    ..As a test, we used a three-stage strategy to screen compounds from the National Cancer Institute's repository for agents that are selectively toxic to double-strand break repair-deficient yeast cells...
  16. pmc Identification and characterization of small-molecule inhibitors of hepsin
    John R Chevillet
    Division of Human Biology, Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue N C3 168, Seattle, WA 98109 1024, USA
    Mol Cancer Ther 7:3343-51. 2008
    ..These compounds may be used as leads to develop even more potent and specific inhibitors of hepsin to prevent prostate cancer progression and metastasis...
  17. ncbi request reprint Disruption of protein-membrane binding and identification of small-molecule inhibitors of coagulation factor VIII
    P Clint Spiegel
    Graduate Program in Biomolecular Structure and Design, University of Washington, Seattle, Washington 98195, USA
    Chem Biol 11:1413-22. 2004
    ..These results indicate that this and related compounds may be used as leads to develop novel antithrombotic agents...
  18. pmc Identification of FDA-approved drugs and bioactives that protect hair cells in the zebrafish (Danio rerio) lateral line and mouse (Mus musculus) utricle
    Henry C Ou
    Virginia Merrill Bloedel Hearing Research Center, University of Washington, Box 357923, Seattle, WA 98195, USA
    J Assoc Res Otolaryngol 10:191-203. 2009
    ....
  19. pmc Chemical screening for hair cell loss and protection in the zebrafish lateral line
    Allison B Coffin
    Virginia Merrill Bloedel Hearing Research Center, University of Washington, Seattle, Washington 98195 7923, USA
    Zebrafish 7:3-11. 2010
    ..We discuss chemical screens to identify compounds that induce hair cell loss and others that protect hair cells from known toxins and the potential application of these screens to human medicine...

Research Grants3

  1. NOVEL DOUBLE STRAND BREAK PRODUCING COMPOUNDS
    Julian Simon; Fiscal Year: 2001
    ..The yeast experiments will involve both classical genetic approaches and genome-wide analyses based on DNA microarray technology. ..
  2. STRATEGIES FOR CONTEXT SPECIFIC ANTICANCER THERAPIES
    Julian Simon; Fiscal Year: 2002
    ..Together, the studies outlined in our Specific Aims, will constitute the first step in testing the hypothesis of context-specific toxicity in cancer chemotherapy. ..
  3. New mitosis specific anticancer agents
    Julian Simon; Fiscal Year: 2005
    ..Through these convergent studies we hope to identify new mitosis-specific anticancer agents, their targets and the contexts in which these compounds are most effective. ..